Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
Interferon-alpha-2b (IFNalpha2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the management of IFN toxicities. An international group of experts with extensive personal experience in the use of IFNs worked together to develop practical guidelines for the use of IFNs. Practical recommendations were developed for patient education on the use of IFN; initial patient assessment and monitoring, including contraindications to the use of IFN, monitoring and managing adverse events, and IFN dose modification and discontinuation; IFN injection procedures; treatment of elderly patients; and use during pregnancy and nursing. Successful adjuvant therapy of melanoma with high-dose IFN requires close compliance with the treatment regimen. Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment.
Hauschild
Axel
A
Department of Dermatology, University of Kiel, Kiel, Germany.
Gogas
Helen
H
Tarhini
Ahmad
A
Middleton
Mark R
MR
Testori
Alessandro
A
Dréno
Brigitte
B
Kirkwood
John M
JM
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D015551:Autoimmunity; D002986:Clinical Trials as Topic; D017408:Guidelines as Topic; D006266:Health Education; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy*; D001523:Mental Disorders / Q000139:chemically induced; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins